NCT07386015 Etiology-Phenotype-Outcome Pathway Study on Freezing of Gait (FOG)
| NCT ID | NCT07386015 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Tianjin Huanhu Hospital |
| Condition | Freezing of Gait |
| Study Type | OBSERVATIONAL |
| Enrollment | 700 participants |
| Start Date | 2026-02-28 |
| Primary Completion | 2029-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 700 participants in total. It began in 2026-02-28 with a primary completion date of 2029-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is a prospective, multicenter, observational cohort (patient registry) designed to better understand freezing of gait (FOG), a disabling walking problem that can occur in Parkinson's disease and other related neurological conditions.The purpose of this registry is to collect long-term clinical information from patients with freezing of gait or gait and balance problems, and to explore how different causes of FOG are related to symptoms, walking patterns, falls, disease progression, and outcomes over time. The study will include participants with Parkinson's disease and other conditions associated with freezing of gait.Participants will receive standard medical care as determined by their treating physicians. No experimental drugs or study-related treatments will be assigned as part of this registry. Clinical information will be collected during routine visits and follow-up assessments, including questionnaires, walking and balance evaluations, video recordings, and other commonly used clinical tests.The information collected in this study may help improve the understanding of freezing of gait, support better risk assessment for falls, and guide future research and clinical management strategies for patients with gait and balance disorders.
Eligibility Criteria
Inclusion Criteria: 1. Age 30-85 years 2. Presence of freezing of gait or non-freezing gait or balance impairment 3. Diagnosis of Parkinson's disease or related parkinsonian disorders according to established international criteria (including PD, PSP, MSA, DLB, CBD, vascular parkinsonism, or idiopathic normal pressure hydrocephalus) 4. Ability to complete gait and balance assessment tasks independently or with assistance 5. Ability and willingness to provide written informed consent Exclusion Criteria: 1. Severe dementia (Mini-Mental State Examination score \< 10) 2. Severe psychiatric disorders interfering with study participation 3. Severe cardiopulmonary, musculoskeletal, or other medical conditions significantly affecting gait safety 4. Stroke, fracture, or other major medical events within the past 3 months 5. Inability to comply with follow-up procedures 6. Refusal of video or speech data collection
Contact & Investigator
Peipei Liu, MD
PRINCIPAL INVESTIGATOR
Tianjin Huanhu Hospital
Frequently Asked Questions
Who can join the NCT07386015 clinical trial?
This trial is open to participants of all sexes, aged 30 Years or older, up to 85 Years, studying Freezing of Gait. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07386015 currently recruiting?
Yes, NCT07386015 is actively recruiting participants. Contact the research team at pddoctorpipi2021@163.com for enrollment information.
Where is the NCT07386015 trial being conducted?
This trial is being conducted at Tianjin, China.
Who is sponsoring the NCT07386015 clinical trial?
NCT07386015 is sponsored by Tianjin Huanhu Hospital. The principal investigator is Peipei Liu, MD at Tianjin Huanhu Hospital. The trial plans to enroll 700 participants.